New inhaled therapy aims to ease lung blood pressure

NCT ID NCT04691154

Ongoing Disease control Sponsor: Liquidia Technologies, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new inhaled drug called L606 (liposomal treprostinil) in 28 adults with pulmonary arterial hypertension or PH-ILD. The goal is to see if it is safe and tolerable when taken twice daily, both short-term and over a year. Participants either switch from another inhaled drug or start L606 for the first time.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: liposomal treprostinil inhalation suspension (L606)
What this could lead to: If successful, this could offer a safer, more tolerable inhaled treatment option for people with pulmonary arterial hypertension or PH-ILD, potentially improving daily management.
What could go wrong: This is a small, open-label safety study with only 28 participants, so results may not apply broadly. Side effects from treprostinil can include headache, nausea, and jaw pain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PULMONARY ARTERIAL HYPERTENSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pulmonary arterial hypertension pulmonary hypertension owing to lung disease and/or hypoxia Respiratory Aspiration

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PULMONARY ARTERIAL HYPERTENSION PULMONARY HYPERTENSION DUE TO LUNG DISEASES

Contacts and locations

Show contact details

Locations

Arizona Pulmonary Specialists

Scottsdale, Arizona, 85258, United States
Baylor Scott and White Research Institute

Temple, Texas, 76508, United States
Icahn School of Medicine at Mount Sinai

New York, New York, 10029-6504, United States
Mayo Clinic Jacksonville

Jacksonville, Florida, 32224, United States
Summit Health Eastside Clinic

Bend, Oregon, 97701, United States
University of Cincinnati Medical Center

Cincinnati, Ohio, 45267, United States
University of South Florida

Tampa, Florida, 33606, United States
VA Greater Los Angeles Healthcare

Los Angeles, California, 90073, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.